Talis Biomedical Corp
Change company Symbol lookup
Select an option...
TLIS Talis Biomedical Corp
SFT Shift Technologies Inc
KMB Kimberly-Clark Corp
NURO NeuroMetrix Inc
OTTW Ottawa Savings Bancorp Inc
HMC Honda Motor Co Ltd
PAVMZ PAVmed Series Z Equity Warrants Exp 30 Apr 2024 *W EXP 04/30/2024
FFBW Ffbw Inc
CIB Bancolombia SA
TARA Protara Therapeutics Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap Growth
Company profile

Talis Biomedical Corporation is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. The Company is engaged in developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system consists of compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy and be operated by an untrained user. It is also focused on developing Talis One assay kits for respiratory infections, and infections related to women's health and sexually transmitted infections (STIs). It is also developing influenza A and influenza B tests to be included as part of a respiratory panel with its COVID-19 assay (Respiratory Panel), as well as exploring adding a respiratory syncytial virus (RSV) test.

Closing Price
$0.835
Day's Change
0.023 (2.83%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.8472
Day's Low
0.811
Volume
(Light)
Volume:
71,272

10-day average volume:
278,926
71,272

Company Profile

Talis Biomedical Corporation is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. The Company is engaged in developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system consists of compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy and be operated by an untrained user. It is also focused on developing Talis One assay kits for respiratory infections, and infections related to women's health and sexually transmitted infections (STIs). It is also developing influenza A and influenza B tests to be included as part of a respiratory panel with its COVID-19 assay (Respiratory Panel), as well as exploring adding a respiratory syncytial virus (RSV) test.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
4.93x
Price/Book (MRQ)
0.11x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

June 2022
Current Month
804.3K
Previous Month
798.5K
Percent of Float
3.37%
Days to Cover
4.1095 Days

Share Information

TLIS is in a share class of common stock
Float
23.9M
Shares Outstanding
26.6M
Institutions Holding Shares
74
63.18%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

No cash flow information available.

Company Officers

  • Robert KelleyCEO
  • Rustem F. Ismagilov
  • J. Roger MoodyCFO
  • Felix J. Baker
  • Raymond Cheong

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.